


REMARKS

Currently claims 1-25 are pending. Applicants amend claims 16, 18-19, and 24-25 to reduce the filing fee by, *inter alia*, removing multiple dependency. Claims 9-14 are amended to correct an error in the claims. Claims 21-23 are cancelled as being inappropriate to US practice. Accordingly, claims 1-20 and 24-25 are presented for examination. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,


John L. Lemanowicz
Attorney for Applicant
Registration No. 37,380

Date:
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8247
Facsimile: 919-483-7988